Spectral CT Combined With MSI for Predicting Regional Lymph Node Metastasis in Gastric Cancer

NCT07565818 | Active Not Recruiting

• 1 other identifier: KYLX2025-296
• Study Type: interventional
• Target: 260
• Locations: 1 country
• Sites: 1

Brief Summary

This study prospectively collected spectral CT imaging data and clinical information related to gastric cancer, evaluated the diagnostic efficacy of its image quality for regional lymph nodes in gastric cancer, and explored its application value in the N staging of gastric cancer with different MSI statuses, so as to provide a more accurate evidence for clinical diagnosis, promote the development of individualized treatment for gastric cancer, and ultimately improve the prognosis of patients.

Conditions

Gastric Cancer

Outcome Measures

Primary Outcomes (1)

• Pathological N stage

  The lymph node status confirmed by surgical pathology was used as the reference standard

  1 day

Study Arms (1)

Spectral CT combined with MSI for predicting regional lymph node metastasis in gastric cancer

EXPERIMENTAL

Medical images and clinical data related to gastric cancer were prospectively collected using a Philips Quark CT scanner, and its diagnostic accuracy and clinical application value in gastric cancer patients with different MSI statuses were evaluated to achieve accurate staging of gastric cancer. Patients diagnosed with gastric cancer at Yunnan Cancer Hospital from August 2025 to December 2026 were consecutively enrolled. After undergoing Philips Quark CT scanning, the N stage of gastric cancer was independently assessed by two radiologists, and statistical analysis was subsequently performed for the final results.

Diagnostic Test: o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses

Interventions

o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses DIAGNOSTIC_TEST

Abdominal CT scans were performed in addition to conventional treatment regimens

Spectral CT combined with MSI for predicting regional lymph node metastasis in gastric cancer

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• (a)Patients with gastric adenocarcinoma confirmed by histopathological biopsy and definite microsatellite status determined by immunohistochemistry (IHC);
• (b)Abdominal dual-phase Quark CT scanning was performed within 2 weeks before surgery;
• (c)aged ≥ 18 years old

You may not qualify if:

• (a)Combined with other primary tumors;
• (b) The image quality does not meet the diagnostic criteria;
• (c)Those who cannot tolerate CT examination.

Sponsors & Collaborators

• Yunnan Cancer Hospital: lead

Study Sites (1)

Yunnan Cancer Hospital

Kunming, Yunnan, China

Location

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Officials

• Ye Lianhua, Study Director

  Ethics Committee of Yunnan Provincial Cancer Hospital

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 27, 2026
• First Posted: May 4, 2026
• Study Start: August 4, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: May 4, 2026

Record last verified: 2025-12

Locations

CN (1)